# D. Ross Camidge

Source: https://onco.cc/people/ross-camidge/  
OnCo record `ross-camidge` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the crizotinib and brigatinib trials that defined ALK-targeted lung cancer therapy.

## Summary

Ross Camidge led the first crizotinib expansion cohort in ALK-positive lung cancer and was principal investigator of the ALTA and ALTA-1L brigatinib trials, and senior author on ALEX (alectinib). He has championed CNS-specific endpoints and ctDNA monitoring in oncogene-driven disease. He directs thoracic oncology research at the University of Colorado.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: lung; alk; targeted-therapy
- Role: Joyce Zeff Chair in Lung Cancer Research, University of Colorado Cancer Center
- Specialisms: ALK-positive lung cancer; Oncogene-driven NSCLC; Brain metastases; Trial design

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Camidge%20DR%5BAuthor%5D%20ALK%20lung

## Connected records

- cancers: [ALK-positive non-small-cell lung cancer](https://onco.cc/cancers/alk-positive-nsclc/), [MET exon 14 and MET-amplified non-small-cell lung cancer](https://onco.cc/cancers/met-altered-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [ROS1-positive non-small-cell lung cancer](https://onco.cc/cancers/ros1-positive-nsclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [ALK](https://onco.cc/targets/alk/)
- drugs: [Lorlatinib](https://onco.cc/drugs/lorlatinib/)
- institutions: [University of Colorado Cancer Center](https://onco.cc/institutions/colorado-cancer-center/)
- trials: [ALEX](https://onco.cc/trials/alex/), [ALTA](https://onco.cc/trials/alta/), [ALTA-1L](https://onco.cc/trials/alta-1l/), [CROWN](https://onco.cc/trials/crown/)
- key papers: [Brigatinib in patients with crizotinib-refractory ALK-positive non-small-cell lung cancer: a randomized, multicenter phase II trial (ALTA)](https://onco.cc/key-papers/paper-alta-jco-2017/), [First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer](https://onco.cc/key-papers/paper-shaw-crown-lorlatinib-crizotinib-nejm-2020/)

---
JSON: https://onco.cc/api/v1/entities/ross-camidge.json